Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
How do you balance infection risk in patients with immune-mediated liver disease on chronic immunosuppression (ex: prednisone, AZA, MMF, etc)?
Related Questions
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
How will the recent withdrawal of Ocaliva for the treatment of PBC impact your therapeutic and management plan for these patients?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
In a serologic evaluation for immune-mediated liver disease, what further workup do you pursue when low immunoglobulins are identified?
What is your strategy to manage pruritus in patients with cholestatic liver disease?
What patient factors guide your selection of maintenance therapies for a patient with autoimmune hepatitis?
What is your strategy in the management of patients with autoimmune hepatitis who failed azathioprine therapy and what parameters do you monitor with what frequency?
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
